Phase I/II trial of vandetanib and bortezomib in adults with locally advanced or metastatic medullary thyroid cancer: Phase I results.

被引：3
|
作者：
Gramza, A. W. [1 ]
Wells, S. A. [1 ]
Balasubramaniam, S. [1 ]
Fojo, A. T. [1 ]
机构：
[1] NCI, NIH, Bethesda, MD 20892 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 15期
关键词：
D O I：
10.1200/jco.2011.29.15_suppl.5565
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5565
引用
收藏
页数：1
相关论文
共 50 条
  • [21] SAFETY AND TOLERABILITY OF VANDETANIB IN JAPANESE PATIENTS WITH MEDULLARY THYROID CANCER: A PHASE I/II OPEN-LABEL STUDY
    Uchino, Keita
    Komoda, Masato
    Tomomatsu, Junichi
    Okamoto, Takahiro
    Horiuchi, Kiyomi
    Tsuji, Akihito
    Ito, Yasuhiro
    Todo, Takuya
    Rito, Ki
    Takahashi, Shunji
    ENDOCRINE PRACTICE, 2017, 23 (02) : 149 - 156
  • [22] Phase II trial of sorafenib for advanced or metastatic medullary thyroid carcinoma and anaplastic thyroid carcinoma
    Ito, Ken-ichi
    ANNALS OF ONCOLOGY, 2016, 27
  • [23] Phase I/II trial of sorafenib combined with FOLFOX4 in untreated patients with advanced gastric adenocarcinoma: Phase I results.
    Chi, Yihebali
    Yang, Jianliang
    Du, Feng
    Yang, Sheng
    Sun, Yongkun
    Shi, Yuankai
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [24] Phase I/II trial of crolibulin and cisplatin in solid tumors with a focus on anaplastic thyroid cancer: Phase I results
    Gramza, Ann Wild
    Balasubramaniam, Sanjeeve
    Fojo, Antonio Tito
    Ward, Jean
    Wells, Samuel A.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [25] A phase I/II trial of concurrent immunotherapy with chemoradiation in locally advanced larynx cancer
    Frankart, Andrew J.
    Sadraei, Nooshin Hashemi
    Huth, Brad
    Redmond, Kevin P.
    Barrett, William L.
    Kurtzweil, Nicky
    Riaz, Muhammad K.
    Wise-Draper, Trisha
    Rodriguez, Cristina P.
    Adelstein, David J.
    Takiar, Vinita
    LARYNGOSCOPE INVESTIGATIVE OTOLARYNGOLOGY, 2022, 7 (02): : 437 - 443
  • [26] Phase I results of the phase I/II study of pembrolizumab in combination with binimetinib in patients with unresectable locally advanced or metastatic triple-negative breast cancer
    Chumsri, Saranya
    Polley, Mei-Yin
    Mathur, Pulkit
    Reis, Aline
    Tenner, Kathleen S.
    Weidner, Morgan
    Advani, Pooja
    Moreno-Aspitia, Alvaro
    Perez, Edith A.
    Knutson, Keith L.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (05)
  • [27] A phase I/II study of dovitinib (TKI258), a FGFR and VEGFR inhibitor, in patients (pts) with advanced or metastatic rental cell cancer: Phase I results.
    Angevin, E.
    Lin, C.
    Pande, A. U.
    Lopez, J. A.
    Gschwend, J.
    Harzstark, A. L.
    Shi, M.
    Anak, O.
    Escudier, B. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [28] Cabozantinib and vandetanib for unresectable locally advanced or metastatic medullary thyroid cancer: a systematic review and economic model
    Tappenden, Paul
    Carroll, Christopher
    Hamilton, Jean
    Kaltenthaler, Eva
    Wong, Ruth
    Wadsley, Jonathan
    Moss, Laura
    Balasubramanian, Sabapathy
    HEALTH TECHNOLOGY ASSESSMENT, 2019, 23 (08) : 1 - +
  • [29] A multicenter, phase II trial of everolimus in locally advanced or metastatic thyroid cancer of all histologic subtypes
    Lim, S. M.
    Chang, H.
    Yoon, M. J.
    Hong, Y. K.
    Kim, H.
    Chung, W. Y.
    Park, C. S.
    Nam, K. H.
    Kang, S. W.
    Kim, M. K.
    Kim, S. B.
    Lee, S. H.
    Kim, H. G.
    Na, I. I.
    Kim, Y. S.
    Choi, M. Y.
    Kim, J. G.
    Park, K. U.
    Yun, H. J.
    Kim, J. H.
    Cho, B. C.
    ANNALS OF ONCOLOGY, 2013, 24 (12) : 3089 - 3094
  • [30] Phase I trial of combination sorafenib and tipifarnib: The experience in advanced differentiated thyroid cancer (DTC) and medullary thyroid cancer (MTC)
    Cabanillas, M. E.
    Kurzrock, R.
    Sherman, S. I.
    Tsimberidou, A. M.
    Waguespack, S.
    Naing, A.
    Busaidy, N.
    Gagel, R.
    Wright, J. J.
    Hong, D. S.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
12345